Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afamelanotide in variegate porphyria-related skin disease
NL-OMON54663Phase 2Completed
- Sponsor
- Clinuvel Pharmaceuticals
- Start
- Mar 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Afamelanotide in variegate porphyria (VP), sponsored by Clinuvel Pharmaceuticals. Primary endpoint: Change in skin disease severity by 11-point VAS IGA. Started Mar 2023; status: completed.
02
Drugs
Afamelanotide
03
Conditions
variegate porphyria (VP)
Beyond the preview
Go deeper on NL-OMON54663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54663.